FOLH1 and prostate carcinoma: Ongoing studies, such as Canadian Clinical Trials Group (CCTG) PR.21, PSMAddition, and PSMAfore, should help to address the optimal sequencing of 177Lu-PSMA-617 in the current treatment paradigms for advanced prostate cancer [11].